Cell Biotech Co., Ltd · KRX:049960
Cell Biotech — Q1 2025 Earnings Presentation
8 slides from Cell Biotech's earnings presentation, May 2025
Slide 1: 2025 1Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2025 1Q Earnings Release 2025. 05. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual result
Slide 2: Revenue down 13.9% to KRW 11.2 billion, operating profit up 27.1%
CELL BIOTECH Revenue down 13.9% to KRW 11.2 billion, operating profit up 27.1% to KRW 1.4 billion Domestic revenue down 17.7%, overseas revenue down 10.1% Duolac brand sales down 2.8% to KRW 6.4 billion, OEM/ODM sales down 33.9% to KRW 3.5 billion, Raw material sales dawn 11.7% to KRW 1.4 billion (u
Slide 3: 1Q revenue KRW 12.2 billion, yoy -13.9%, qoq -7.6%
CELL BIOTECH 1q revenue KRW 12.2 billion, yoy -13.9%, qoq -7.6% Quarterly revenue Full year revenue (unit : KRW mil) (unit : KRW mil) 53,787 50,526 14,841 49,913 13,660 12,845 12,440 13,038 12,558 12,160 12,155 11,229 46,873 2021 2022 2023 2024 3
Slide 4: Quarterly profit and full year profit
CELL BIOTECH 1q operating profit KRW 1.4 billion, yoy +27.1% Net Profit KRW +2.1 bil. Quarterly profit Full year profit (unit : KRW mil) 15,127 OP NP 6,860 10,314 4,040 9,682 3,260 2,857 2,961 2,707 2,510 2,384 2,080 7,258 2,070 6,796 1,812 6,273 6,304 1,362 1,070 1,130 1,036 960 '23.1Q '23.2Q '23.3
Slide 5: 1Q revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH 1q revenue of Duolac brand -2.8% to 6.4 KRW bil., OEM/ODM -33.9% to 3.5 KRW bil., and raw material -11.7% to 1.4 KRW bil. 20,000 (unit : KRW mil) 15,000 10,000 5,000 - 22.1Q 22.2Q 22.3Q 22.4Q 23.1Q 23.2Q 23.3Q 23.4Q 24.1Q 24.2Q 24.3Q 24.4Q 25.1Q Duolac-domestic Duolac-overseas OEM/ODM r
Slide 6: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 11 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in clinical phase 1 IND submitted (Mar 5, 2021) the world for 11 consecutive years 2) Acquisition European patent of
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria secured 2) Cellbiotech, Probiotics Leading... Global Leap FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2024 1q 2025 1q 2024 .12 2025 .1Q Amount Ratio Amount Ratio Assets 1,304 1,326 Revenue 130.4 100 112.3 100 Current Assets 972 1,001 Gross profit 93.4 71.6 79.8 71.1 Non current Assets 332